Characterization of Equilibrative Nucleoside Transport of the Pancreatic Cancer Cell Line: Panc-1
Sıla Appak Başköy1,2, Amardeep Khunkhuna3, Bianca Scuric1
1Toronto Metropolitan University Faculty of Science, Department of Chemistry and Biology, Toronto, Ontario, Canada.
Objectives:
Gemcitabine, a first-line chemotherapeutic nucleoside analog drug (NAD) for pancreatic cancer, faces limitations due to drug resistance. Characterizing pancreatic cancer cells' transport characteristics may help identify the mechanisms behind drug resistance, and develop more effective therapeutic strategies. Therefore, in this study, we aimed to determine the nucleoside transport properties of Panc-1 cells, one of the commonly used pancreatic adenocarcinoma cell lines.
Materials And Methods:
To assess the presence of equilibrative nucleoside transporter-1 (ENT-1) in Panc-1 cells, we performed immunofluorescence staining, western blot analysis, and S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding assays. We also conducted standard uptake assays to measure the sodium-independent uptake of [3H]-labeled chloroadenosine, hypoxanthine, and uridine. In addition, we determined the half-maximal inhibitory concentration (IC50) of gemcitabine. Statistical analyses were performed using GraphPad Prism version 8.0 for Windows.
Results:
The sodium-independent uptake of [3H]-labeled chloroadenosine, hypoxanthine, and uridine was measured using standard uptake assays, and the transport rates were determined as 111.1 ± 3.4 pmol/mg protein/10 s, 62.5 ± 4.8 pmol/mg protein/10 s, and 101.3 ± 2.5 pmol/mg protein/10 s, respectively. Furthermore, the presence of ENT-1 protein was confirmed using NBTI binding assays (Bmax 1.52 ± 0.1 pmol/mg protein; equilibrium dissociation constant 0.42 ± 0.1 nM). Immunofluorescence assays and western blot analysis also revealed ENT-1 in Panc-1 cells. The determined IC50 of gemcitabine in Panc-1 cells was 2 μM, indicating moderate sensitivity.
Conclusion:
These results suggest that Panc-1 is a suitable preclinical cellular model for studying NAD transport properties and potential therapies in pancreatic cancer and pharmaceutical research.
Insights
Panc-1 cells exhibit nucleoside transporter-1 (ENT-1) expression, crucial for gemcitabine uptake in pancreatic cancer research. This finding supports Panc-1 cells as a valuable model for developing novel pancreatic cancer therapies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Gemcitabine is a primary treatment for pancreatic cancer but faces drug resistance.
- Understanding nucleoside transport in cancer cells is key to overcoming resistance.
- Panc-1 cells are a widely used model for pancreatic adenocarcinoma.
Purpose of the Study:
- To characterize the nucleoside transport properties of Panc-1 cells.
- To investigate the expression and function of equilibrative nucleoside transporter-1 (ENT-1) in Panc-1 cells.
- To assess gemcitabine sensitivity in Panc-1 cells.
Main Methods:
- Immunofluorescence staining, western blot, and NBTI binding assays to detect ENT-1.
- Sodium-independent uptake assays for radiolabeled nucleosides (chloroadenosine, hypoxanthine, uridine).
- Gemcitabine IC50 determination.
Main Results:
- Panc-1 cells demonstrated significant sodium-independent uptake of chloroadenosine, hypoxanthine, and uridine.
- ENT-1 protein expression was confirmed by NBTI binding, immunofluorescence, and western blot.
- The IC50 of gemcitabine in Panc-1 cells was 2 μM, indicating moderate sensitivity.
Conclusions:
- Panc-1 cells express functional ENT-1, mediating nucleoside transport.
- These cells are a suitable preclinical model for studying nucleoside analog drug transport in pancreatic cancer.
- Findings support further research into ENT-1 targeting for enhanced pancreatic cancer therapy.
